Valuation: Zentalis Pharmaceuticals, Inc.

Market Cap 13Cr 12Cr 11Cr 10Cr 19Cr 1.25TCr 20Cr 136.1Cr 54Cr 674.07Cr 50Cr 49Cr 2.13TCr P/E 2026 *
-0.75x
P/E 2027 * -0.82x
Enterprise Value -8.04Cr -7.34Cr -6.78Cr -6.12Cr -12Cr -751.58Cr -12Cr -82Cr -32Cr -405.67Cr -30Cr -30Cr -1.28TCr EV / Sales 2026 *
-
EV / Sales 2027 * -16.9x
Free-Float
78.95%
Yield 2026 *
-
Yield 2027 * -
1 day-8.72%
1 week-28.04%
Current month-30.61%
1 month-36.15%
3 months-63.04%
6 months-62.53%
Current year+0.74%
1 week 1.36
Extreme 1.36
1.8
1 month 1.36
Extreme 1.36
2.47
Current year 1.32
Extreme 1.32
6.95
1 year 1.28
Extreme 1.28
6.95
3 years 1.01
Extreme 1.01
18.07
5 years 1.01
Extreme 1.01
85.95
10 years 1.01
Extreme 1.01
87.19
Manager TitleAgeSince
Chief Executive Officer 62 13/11/2024
Director of Finance/CFO - 13/11/2024
Chief Tech/Sci/R&D Officer 51 13/11/2024
Director TitleAgeSince
Chairman 61 16/05/2022
Director/Board Member 44 09/02/2021
Director/Board Member 59 12/09/2022
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Free

Chief Technology Officer

9,727 0.0103%
14/08/26 Buy 43,35,000 4.5791%
26/05/26 Free

Director

1,14,200 0.1604%
Change 5-day change 1-year change 3-year change Capi.($)
-8.72%-28.04%0.00%-88.02% 13Cr
-1.34%-3.09%+56.10%+68.83% 6.55TCr
-0.95%-3.93%+6.82%+88.99% 5.89TCr
+0.62%+0.63%+26.55%+87.63% 5.52TCr
-2.34%-3.90%+10.90%+115.97% 4.61TCr
+0.09%-6.08%+18.67%+25.90% 4.25TCr
-2.58%+0.24%+18.54%+41.28% 3.56TCr
-1.76%-11.56%+126.44%+649.27% 3.46TCr
-0.04%-0.93%+76.71%+57.52% 3.25TCr
-1.69%-0.79%-40.58%+382.68% 2.63TCr
Average -1.85%-5.87%+30.01%+143.01% 4TCr
Weighted average by Cap. -1.01%-3.30%+33.46%+143.15%

Financials

2026 *2027 *
Net sales - 16.25L 14.82L 13.71L 12.37L 23.29L 15Cr 24.21L 1.66Cr 65.43L 8.2Cr 60.97L 59.7L 26Cr
Net income -14Cr -13Cr -12Cr -11Cr -20Cr -1.32TCr -21Cr -144.33Cr -57Cr -714.8Cr -53Cr -52Cr -2.26TCr -16Cr -15Cr -13Cr -12Cr -23Cr -1.49TCr -24Cr -162.06Cr -64Cr -802.62Cr -60Cr -58Cr -2.53TCr
Net Debt -21Cr -20Cr -18Cr -16Cr -31Cr -2TCr -32Cr -218.01Cr -86Cr -1.08TCr -80Cr -79Cr -3.41TCr -16Cr -15Cr -14Cr -12Cr -23Cr -1.51TCr -24Cr -164.08Cr -65Cr -812.65Cr -60Cr -59Cr -2.57TCr
Projected Income Statement - Annual - Zentalis Pharmaceuticals, Inc.
Logo Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Employees
106
Date Price Change Volume
18/26/18 $1.360 -8.72% 12,10,588
17/26/17 $1.490 -6.88% 12,96,075
16/26/16 $1.600 -5.88% 14,49,257
13/26/13 $1.700 +1.19% 13,00,089
12/26/12 $1.680 -11.11% 16,25,036
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Zentalis Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
1.360USD
Average target price
7.444USD
Spread / Average Target
+447.39%
  1. Stock Market
  2. Stocks
  3. ZNTL Stock